Susquehanna Fundamental Investments LLC Acquires Shares of 53,938 Merus (NASDAQ:MRUS)

Susquehanna Fundamental Investments LLC acquired a new stake in Merus (NASDAQ:MRUS - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund acquired 53,938 shares of the biotechnology company's stock, valued at approximately $2,268,000. Susquehanna Fundamental Investments LLC owned 0.08% of Merus at the end of the most recent quarter.

Several other hedge funds have also made changes to their positions in MRUS. Franklin Resources Inc. grew its position in shares of Merus by 7.1% during the third quarter. Franklin Resources Inc. now owns 2,256,504 shares of the biotechnology company's stock worth $117,722,000 after buying an additional 150,341 shares in the last quarter. Lord Abbett & CO. LLC boosted its position in shares of Merus by 83.0% in the 3rd quarter. Lord Abbett & CO. LLC now owns 723,988 shares of the biotechnology company's stock valued at $36,171,000 after purchasing an additional 328,316 shares during the period. Harbor Capital Advisors Inc. grew its position in shares of Merus by 2.2% during the fourth quarter. Harbor Capital Advisors Inc. now owns 43,208 shares of the biotechnology company's stock worth $1,817,000 after acquiring an additional 921 shares during the last quarter. Harbour Capital Advisors LLC purchased a new position in Merus during the 4th quarter worth $360,000. Finally, Avior Wealth Management LLC acquired a new position in Merus in the 4th quarter valued at about $76,000. Institutional investors and hedge funds own 96.14% of the company's stock.

Merus Stock Performance

MRUS traded down $0.65 on Monday, reaching $43.54. 58,960 shares of the company's stock were exchanged, compared to its average volume of 693,306. The company has a market cap of $3.01 billion, a price-to-earnings ratio of -11.02 and a beta of 0.94. Merus has a twelve month low of $33.19 and a twelve month high of $61.61. The company's 50 day moving average is $43.96 and its 200-day moving average is $44.43.

Merus (NASDAQ:MRUS - Get Free Report) last issued its quarterly earnings data on Thursday, February 27th. The biotechnology company reported ($0.41) EPS for the quarter, topping analysts' consensus estimates of ($0.89) by $0.48. The company had revenue of $9.14 million for the quarter, compared to analysts' expectations of $10.57 million. Merus had a negative return on equity of 38.89% and a negative net margin of 680.61%. Sell-side analysts forecast that Merus will post -3.85 EPS for the current year.

Analyst Ratings Changes

Several analysts have recently weighed in on MRUS shares. Guggenheim reaffirmed a "buy" rating and issued a $109.00 target price on shares of Merus in a report on Friday, March 28th. Bank of America cut their price target on Merus from $73.00 to $70.00 and set a "buy" rating for the company in a research note on Monday, March 10th. Wells Fargo & Company began coverage on shares of Merus in a research report on Friday, February 7th. They set an "overweight" rating and a $91.00 target price for the company. Piper Sandler assumed coverage on Merus in a research report on Thursday, February 13th. They set an "overweight" rating and a $84.00 price objective for the company. Finally, William Blair reissued an "outperform" rating on shares of Merus in a research note on Monday, April 28th. One equities research analyst has rated the stock with a sell rating, fourteen have assigned a buy rating and two have assigned a strong buy rating to the company's stock. According to MarketBeat.com, the stock currently has a consensus rating of "Buy" and a consensus target price of $85.31.

About Merus

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.